Boddy, Alan - University of Sydney

研究领域

My primary research interests are in the understanding of how the pharmacology of cancer drugs (including drug metabolism, pharmacogenetics and other sources of variability) influences treatment outcomes, and how best to implement such understanding to improve patient care. My interest also include: Drug interactions with cancer treatments and with concomitant medicines. The interplay between genetic variation and other sources of pharmacological variability. The pharmacology of drugs in first-in-human studies. Analytical methods for drug analysis. Pharmacodynamic and biomarker assays in the optimisation of cancer therapy. Implementation of personalised medicine to improve therapy.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Pu, X., Storr, S., Ahmad, N., Chan, S., Moseley, P., Televantou, D., Cresti, N., Boddy, A., Ellis, I., Martin, S. (2016). Calpain-1 is associated with adverse relapse free survival in breast cancer: A confirmatory study. Histopathology, 68(7), 1021-1029. [More Information] Veal, G., Cole, M., Chinnaswamy, G., Sludden, J., Jamieson, D., Errington, J., Malik, G., Hill, C., Chamberlain, T., Boddy, A. (2016). Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. European Journal of Cancer, 55, 56-64. [More Information] Walsh, C., Bonner, J., Johnson, T., Neuhoff, S., Ghazaly, E., Gribben, J., Boddy, A., Veal, G. (2016). Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. British Journal of Clinical Pharmacology, 81(5), 989-998. [More Information] Goulooze, S., Galettis, P., Boddy, A., Martin, J. (2016). Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer Chemotherapy and Pharmacology, 78(1), 209-216. [More Information] Moreno, L., Marshall, L., Pearson, A., Morland, B., Elliott, M., Campbell-Hewson, Q., Makin, G., Halford, S., Acton, G., Ross, P., et al (2015). A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. Clinical Cancer Research, 21(2), 267-273. [More Information] Voller, S., Boos, J., Krischke, M., Wurthwein, G., Kontny, N., Boddy, A., Hempel, G. (2015). Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. Clinical Pharmacokinetics, 54(11), 1139-1149. [More Information] Kim, S., Naskar, D., Kundu, S., Bishop, D., Doble, P., Boddy, A., Chan, K., Wall, I., Chrzanowski, W. (2015). Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer. Scientific Reports, 5, 1-13. [More Information] Oxley, A., Berry, P., Taylor, G., Cowell, J., Hall, M., Hesketh, J., Lietz, G., Boddy, A. (2014). An LC/MS/MS method for stable isotope dilution studies of beta-carotene bioavailability, bioconversion, and vitamin A status in humans. Journal of Lipid Research, 55(2), 319-328. [More Information] Hill, C., Cole, M., Errington, J., Malik, G., Boddy, A., Veal, G. (2014). Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer. Clinical Pharmacokinetics, 53(8), 741-751. [More Information] Jamieson, D., Lee, J., Cresti, N., Jackson, R., Griffin, M., Sludden, J., Verril, M., Boddy, A. (2014). Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5‑fluorouracil. Cancer Chemotherapy and Pharmacology, 74(4), 667-674. [More Information] Krischke, M., Boddy, A., Boos, J. (2014). Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samples. Expert Opinion on Drug Metabolism and Toxicology, 10(6), 825-838. [More Information] Murray, J., Thomas, H., Berry, P., Kyleq, S., Patterson, M., Jones, C., Los, G., Hostomsky, Z., Plummer, E., Boddy, A., et al (2014). Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer, 110(8), 1977-1984. [More Information] Veal, G., Errington, J., Rowbotham, S., Illingworth, N., Malik, G., Cole, M., Daly, A., Pearson, A., Boddy, A. (2013). Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. Clinical Cancer Research, 19(2), 469-479. [More Information] Hill, C., Jamieson, D., Thomas, H., Brown, C., Boddy, A., Veal, G. (2013). Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology, 85(1), 29-37. [More Information] Boddy, A. (2013). Genetics of cisplatin ototoxicity: Confirming the unexplained? Clinical Pharmacology & Therapeutics, 94(2), 198-200. [More Information] Kontny, N., Wurthwein, G., Joachim, B., Boddy, A., Krischke, M., Fuhr, U., Thompson, P., Jorger, M., Schellens, J., Hempel, G. (2013). Population pharmacokinetics of doxorubicin: Establishment of a NONMEM model for adults and children older than 3 years. Cancer Chemotherapy and Pharmacology, 71(3), 749-763. [More Information] Veal, G., Boddy, A. (2012). Carboplatin Dosing in Infants With Retinoblastoma: A Case for Therapeutic Drug Monitoring. Journal of Clinical Oncology, 30(27), 3424-3424. [More Information] Veal, G., Boddy, A. (2012). Chemotherapy in newborns and preterm babies. Seminars in Fetal and Neonatal Medicine, 17(4), 243-248. [More Information] Kontny, N., Boos, J., Würthwein, G., Hempel, G., Boddy, A., Groll, A., Krischke, M. (2012). Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring: Focus on IV Drug Administration. Therapeutic Drug Monitoring, 34(4), 460-466. [More Information] Jarvis, I., Meczes, E., Thomas, H., Edmondson, R., Veal, G., Boddy, A., Ottley, C., Pearson, D., Tilby, M. (2012). Therapy-induced carboplatin–DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochemical Pharmacology, 83(1), 69-77. [More Information]